Status:
RECRUITING
Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
Lead Sponsor:
St. Mary's Research Center, Canada
Conditions:
Postoperative Bleeding
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and...
Detailed Description
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are some of the most common surgical procedures performed in elderly patients, with the main indication being end-stage osteoarthritis. W...
Eligibility Criteria
Inclusion
- ° All adults undergoing primary TKA and THA at St-Mary's Hospital
Exclusion
- Age \< 18 years
- Known hypersensitivity or allergy to TXA
- Previous history of thromboembolic disease
- Active malignancy (all current cancers other than local skin cancer)
- Significant renal disease (hematuria, dialysis, kidney transplant)
- History of convulsions
- Known defective colour vision
- Inability or unwillingness to use MyMobility app
- Unable to communicate in French or English
Key Trial Info
Start Date :
August 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT06208267
Start Date
August 20 2025
End Date
April 1 2027
Last Update
August 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Mary's Hospital Center
Montreal, Quebec, Canada, H3T 1M5